Rac­ing to grab mar­ket share in di­a­betes, No­vo touts its oral semaglu­tide win over Jar­diance in PhI­I­Ia tri­al

No­vo Nordisk’s oral di­a­betes drug semaglu­tide is bear­ing down on one of its ri­vals — out­per­form­ing Jar­diance (em­pagliflozin) in a Phase II­Ia tri­al that could set …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER